Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Wave Life Sciences (WVE) to $30 from $22 and keeps a Buy rating on the shares. The firm says its key opinion leader validation and ...

Integral Ad Science Holding Corp. IAS will release its financial results for the fourth quarter, before the opening bell, on Friday, Feb. 28, 2025. Analysts expect the New York-based company to report ...

Canaccord analyst Kyle Mikson raised the firm’s price target on Caris Life Sciences (CAI) to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness ...

Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public offering at $21.00 ...